This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic ...

Biocartis has announced the launch of its CE-IVD Idylla™ KRAS Mutation Test, a sample-to-result test for the fast, accurate and reproducible detection of 21 relevant mutations in the KRAS oncogene.

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Non-Invasive, Low-Cost Test Provides Early Detection—and Ongoing Monitoring of Previously Diagnosed Patients—Offering New Hope in the Fight Against Cancer SAN DIEGO, Sept. 10, 2015 /PRNewswire ...

PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – Biocartis NV (“Biocartis”), an ...

Background: About 5% of cases of breast cancer and 10% of cases of ovarian cancer are due to an inherited predisposition. Since 1994 it has been possible to test some people at high risk for inherited ...

Mechelen, Belgium, 02 June 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union ...